Clinical trials: Movement Abnormalities
Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
- Trial name
- NCT00199368
- Testing
- Istradefylline ( KW-6002)
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson Disease
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment…
- Trial name
- NCT07145190
- Testing
- SL-APO
- Where
- 12 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Bial - Portela C S.A.
Dementia With Lewy Bodies
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
- Trial name
- COG1201 (NCT05225415)
- Testing
- CT1812
- Where
- 34 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cognition Therapeutics
Parkinson's Disease
Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion
The aim of the study is to evaluate the long-term efficacy, local tolerability and safety of Lisuride applied as subcutaneous infusion compared to placebo in patients with advanced Parkinson's disease with motor fluctuations and…
- Trial name
- NCT00408915
- Testing
- Continuous Subcutaneous Lisuride Infusion
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Axxonis Pharma AG
Parkinson's Disease
Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients
Phytopharm plc is developing Cogane™ which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's…
- Trial name
- NCT00875316
- Testing
- Cogane™ (PYM50028)
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Phytopharm
Healthy Volunteers
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or…
- Trial name
- NCT06088784
- Testing
- ATH-399A, ATH-399A 10 mg, 5 mg ATH-399A capsule
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Parkinson's Disease, Essential Tremor
Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor
This is a 6-week exploratory clinical study, designed to test whether treatment with peroneal electrical trans-cutaneous stimulation can have a beneficial effects on symptoms associated with Parkinson's diseases and essential…
- Trial name
- NCT06036368
- Testing
- Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
- Where
- Czechia
- Volunteers
- 23 people
- Sponsor
- Stimvia s.r.o.
Parkinson Disease
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
Evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic…
- Trial name
- NCT03319485
- Testing
- ExAblate Pallidotomy
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 92 people
- Sponsor
- InSightec
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multiple System Atrophy, MSA
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
- Trial name
- NCT02388295
- Testing
- AZD3241
- Where
- 17 sites in United States, Austria and 5 more
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Parkinson's Disease
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
The purpose of the study is to assess the efficacy and safety of XP21279/Carbidopa in comparison to Sinemet as well as evaluate the pharmacokinetics (PK) of levodopa after administration of XP21279/Carbidopa and Sinemet and to…
- Trial name
- NCT01171313
- Testing
- XP21279 and carbidopa (experimental), Sinemet (comparator)
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- XenoPort, Inc.
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Multiple System Atrophy
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
- Trial name
- MASCOT (NCT06706622)
- Testing
- Amlenetug
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 401 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study
To evaluate DBS device settings and match with the features of the DBS care management software.
- Trial name
- DBS (NCT01750242)
- Testing
- Medtronic DBS system
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- MedtronicNeuro
Essential Tremor
Study to Evaluate SAGE-324 in Participants With Essential Tremor
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremor (ET) in the monotherapy cohort.
- Trial name
- NCT05173012
- Testing
- SAGE-324
- Where
- 51 sites in United States
- Volunteers
- 146 people
- Sponsor
- Sage Therapeutics
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
PARKINSON DISEASE (Disorder)
Short and Long-term Responses of PD Symptoms to Earstim
This is a prospective, multicenter, randomized, two-period study designed to evaluate the safety and effectiveness of the EarStim System for intermittent relief of motor symptoms in patients with Parkinson's disease experiencing…
- Trial name
- NCT07400731
- Testing
- EarStim, EarStim + Standard of care (SOC), Standard of Care (SOC)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Stoparkinson Healthcare Systems LLC
Parkinson's Disease
Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease
To assess the safety of xenotransplantation of NTCELL [immunoprotected (alginate-encapsulated) choroid plexus cells] in patients with Parkinson's disease, assessed over the duration of the study, by monitoring the occurrence of…
- Trial name
- NCT02683629
- Testing
- NTCELL Implantation
- Where
- New Zealand
- Volunteers
- 18 people
- Sponsor
- Living Cell Technologies
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Parkinson Disease, Parkinson's Disease
A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
- Trial name
- NCT07629115
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Innopeutics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.